[go: up one dir, main page]

DE60031686D1 - Pyrazinone, diese verbindungen enthaltende zusammenstellungen - Google Patents

Pyrazinone, diese verbindungen enthaltende zusammenstellungen

Info

Publication number
DE60031686D1
DE60031686D1 DE60031686T DE60031686T DE60031686D1 DE 60031686 D1 DE60031686 D1 DE 60031686D1 DE 60031686 T DE60031686 T DE 60031686T DE 60031686 T DE60031686 T DE 60031686T DE 60031686 D1 DE60031686 D1 DE 60031686D1
Authority
DE
Germany
Prior art keywords
compounds
pyrazinone
compositions containing
caspase
hydrates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60031686T
Other languages
English (en)
Other versions
DE60031686T2 (de
Inventor
Yongxin Han
Andre Giroux
Robert Zamboni
J Mckay
I Bayly
L Grimm
John Colucci
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Canada Inc
Original Assignee
Merck Frosst Canada Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Frosst Canada Ltd filed Critical Merck Frosst Canada Ltd
Application granted granted Critical
Publication of DE60031686D1 publication Critical patent/DE60031686D1/de
Publication of DE60031686T2 publication Critical patent/DE60031686T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE60031686T 1999-07-19 2000-07-17 Pyrazinone, diese verbindungen enthaltende zusammenstellungen Expired - Lifetime DE60031686T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US14446699P 1999-07-19 1999-07-19
US144466P 1999-07-19
US17061499P 1999-12-14 1999-12-14
US170614P 1999-12-14
PCT/CA2000/000833 WO2001005772A1 (en) 1999-07-19 2000-07-17 Pyrazinones, compositions containing such compounds

Publications (2)

Publication Number Publication Date
DE60031686D1 true DE60031686D1 (de) 2006-12-14
DE60031686T2 DE60031686T2 (de) 2007-08-30

Family

ID=26842025

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60031686T Expired - Lifetime DE60031686T2 (de) 1999-07-19 2000-07-17 Pyrazinone, diese verbindungen enthaltende zusammenstellungen

Country Status (9)

Country Link
US (2) US6444811B1 (de)
EP (1) EP1202976B1 (de)
JP (1) JP4749640B2 (de)
AT (1) ATE344249T1 (de)
AU (1) AU773317B2 (de)
CA (1) CA2378834C (de)
DE (1) DE60031686T2 (de)
ES (1) ES2274795T3 (de)
WO (1) WO2001005772A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE344249T1 (de) * 1999-07-19 2006-11-15 Merck Frosst Canada Ltd Pyrazinone, diese verbindungen enthaltende zusammenstellungen
US20020155172A1 (en) * 2000-04-07 2002-10-24 Junying Yuan Methods and compounds for decreasing cell toxicity or death
PE20011350A1 (es) 2000-05-19 2002-01-15 Vertex Pharma PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE)
US20040241782A1 (en) * 2001-01-26 2004-12-02 Eloisa Lopez-Calle Methods and means for detecting enzymatic cleavage and linkage reactions
FR2827288B1 (fr) * 2001-07-12 2003-10-31 Servier Lab Nouveaux derives d'octahydro-2h-pyrido[1,2-a]pyrazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU2003211052A1 (en) 2002-02-11 2003-09-04 Vertex Pharmaceuticals Incorporated Phospholipids as caspase inhibitor prodrugs
EP1499898A2 (de) 2002-04-19 2005-01-26 Vertex Pharmaceuticals Incorporated Regulierung von tnf-alpha
AU2004241602B2 (en) * 2003-05-20 2008-05-08 Syndiant, Inc. Digital backplane
AU2005249503B2 (en) 2003-11-10 2011-08-25 Vertex Pharmaceuticals Incorporated ICE inhibitors for the treatment of autoinflammatory diseases
JP4898658B2 (ja) * 2004-03-12 2012-03-21 バーテックス ファーマシューティカルズ インコーポレイテッド アスパラギン酸アセタールカスパーゼ阻害剤の製造のための方法および中間体
CA2616337A1 (en) 2005-07-28 2007-02-08 Vertex Pharmaceuticals Incorporated Caspase inhibitor prodrugs
KR20080042286A (ko) * 2006-11-09 2008-05-15 주식회사 엘지생명과학 피리다지논 구조를 포함하는 캐스파제 저해제
JP2010535167A (ja) 2007-08-03 2010-11-18 サノフィ−アベンティス カスパーゼイメージングプローブ
EP2262783A2 (de) * 2008-02-21 2010-12-22 Sanofi-Aventis Kovalent bindende sonden zur bilddarstellung
EP2635906A4 (de) 2010-11-05 2014-04-02 Univ Brandeis Ice-hemmende verbindungen und ihre verwendungen
CN109180690A (zh) * 2018-10-15 2019-01-11 烟台显华化工科技有限公司 一类用作蓝色荧光材料的氮杂芳香化合物及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5716929A (en) * 1994-06-17 1998-02-10 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
JP3140790B2 (ja) * 1996-04-23 2001-03-05 メルク エンド カンパニー インコーポレーテッド ピラジノン系トロンビン阻害薬
WO1998008840A1 (en) 1996-08-29 1998-03-05 Merck & Co., Inc. Integrin antagonists
US5981546A (en) * 1996-08-29 1999-11-09 Merck & Co., Inc. Integrin antagonists
CA2263198A1 (en) * 1996-09-06 1998-03-12 Nippon Kayaku Kabushiki Kaisha Novel acetamide derivatives and protease inhibitors
CA2283704A1 (en) 1997-03-24 1998-10-01 Merck & Co., Inc. Thrombin inhibitors
US5866573A (en) 1997-04-21 1999-02-02 Merck & Co., Inc. Pyrazinone thrombin inhibitors
JP2001514227A (ja) 1997-09-05 2001-09-11 メルク エンド カムパニー インコーポレーテッド ピラジノン系トロンビン阻害薬
ATE344249T1 (de) * 1999-07-19 2006-11-15 Merck Frosst Canada Ltd Pyrazinone, diese verbindungen enthaltende zusammenstellungen

Also Published As

Publication number Publication date
JP4749640B2 (ja) 2011-08-17
AU773317B2 (en) 2004-05-20
EP1202976B1 (de) 2006-11-02
DE60031686T2 (de) 2007-08-30
CA2378834C (en) 2009-07-07
CA2378834A1 (en) 2001-01-25
WO2001005772A1 (en) 2001-01-25
US6699856B2 (en) 2004-03-02
ES2274795T3 (es) 2007-06-01
ATE344249T1 (de) 2006-11-15
US20030236402A1 (en) 2003-12-25
US6444811B1 (en) 2002-09-03
JP2003505378A (ja) 2003-02-12
EP1202976A1 (de) 2002-05-08
AU6143200A (en) 2001-02-05

Similar Documents

Publication Publication Date Title
JO2282B1 (en) Oxazole derivatives
DE60031686D1 (de) Pyrazinone, diese verbindungen enthaltende zusammenstellungen
MX2007000028A (es) Derivados de nicotinamida y su uso como agentes terapeuticos.
ECSP066314A (es) Derivados piridilo y su uso como agentes terapéuticos
AP1860A (en) Aryl fused azapolycyclic compounds.
WO2001064639A3 (en) Pde iv inhibiting amides, compositions and pharmaceutical use
AU2003301020A1 (en) Isoquinolinone derivatives and their use as therapeutic agents
GB0413087D0 (en) Therapeutic compounds
TW200609227A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
NO20093464L (no) Nye medikamentblandinger basert pa anti-cholinergisk effektive forbindelser og beta-mimetika
MXPA02012272A (es) Compuestos heterociclicos que son inhibidores de la enzima dipeptidilpeptidasa-iv.
ATE245152T1 (de) Dioxocyclopentylhydroxamsäure
ATE264852T1 (de) Chinolinderivate als antibakterielle mittel
WO2004033455A3 (en) Hemisuccinate salts of heterocyclic dpp-iv inhibitors
TW200517389A (en) Biaryloxymethylarenecarboxylic acids
NO990433L (no) Nye forbindelser og blandinger for behandling av sykdommer i forbindelse med tryptase-aktivitet
NO20050851L (no) Kaspase-inhibitorer og anvendelser derav
WO2007046867A3 (en) Piperidine derivatives and their uses as therapeutic agents
WO2006125194A3 (en) Piperazine derivatives and their uses as therapeutic agents
DE60107832D1 (en) Chromenylmethylpyrimidindiamine als antibakterielle wirkstoffe
ATE444069T1 (de) Chinolin-derivate zur behandlung von mglur5- rezeptor-vermittelten erkrankungen
YU19302A (sh) 4-benzilaminohinolin konjugovan žučnom kiselinom i njegovi heteroanalozi, postupak za njihovu proizvodnju, lekovi koji sadrže ta jedinjenja i njihova primena
TW200732304A (en) Piperidine derivatives
DE60119514D1 (de) Amidderivate der 2-amino-3-hydroxy-4-tert-leucyl-amino-5-phenyl-pentansäure
MA28930B1 (fr) Derives pyridiniques d'indolin-2-one , leur preparation et leur application en therapeutique

Legal Events

Date Code Title Description
8364 No opposition during term of opposition